Last reviewed · How we verify
Cysticide
Cysticide is a Small molecule drug developed by Merck KGaA, Darmstadt, Germany. It is currently in Phase 1 development for Clonorchiasis due to C. Sinensis, Infection by Schistosoma, Opisthorchiasis. Also known as: PZQ, Praziquantel.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Merck KGaA, Darmstadt, Germany is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cysticide |
|---|---|
| Also known as | PZQ, Praziquantel |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Target | Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
- Clonorchiasis due to C. Sinensis
- Infection by Schistosoma
- Opisthorchiasis
- Schistosomiasis due to S. Haematobium
- Schistosomiasis due to S. Japonicum
- Schistosomiasis due to S. Mansoni
- Schistosomiasis due to S. Mekongi
Common side effects
Key clinical trials
- Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal (N/A)
- Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression (NA)
- Impact of Parasitic Infections on Intestinal Epithelial Barrier and Immune Activation Among Persons Living With HIV in Lilongwe, Malawi (NA)
- Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. (NA)
- Praziquantel Pharmacokinetics in Pregnancy and During Lactation (Phase 1)
- Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Rando (Phase 2)
- Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil (Phase 4)
- Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cysticide CI brief — competitive landscape report
- Cysticide updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI
Frequently asked questions about Cysticide
What is Cysticide?
What is Cysticide used for?
Who makes Cysticide?
Is Cysticide also known as anything else?
What development phase is Cysticide in?
What does Cysticide target?
Related
- Target: All drugs targeting Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1
- Manufacturer: Merck KGaA, Darmstadt, Germany — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Clonorchiasis due to C. Sinensis
- Indication: Drugs for Infection by Schistosoma
- Indication: Drugs for Opisthorchiasis
- Also known as: PZQ, Praziquantel
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing